ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Genetic Analysis of a Family With Hereditary Factor V Deficiency Induced by Compound Heterozygous Variants (IVS24+3A>T and p.Asp2222Gly).
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveFactor V(FV) is a critical cofactor in the coagulation cascade. The diagnosis and investigation of novel variant contribute to improving the clinical treatment and management of patient with Factor V deficiency.
methodsCoagulation screening, FV activity, FV antigen levels and thrombin generation assay (TGA) were performed on plateletpoor plasma samples collected from eleven family members. All exons and flanks of F5 gene were analysed by Sanger sequencing and novel variant were confirmed by reverse sequencing. Online bioinformatics tools were used to investigate possible adverse and effects on splicing of proband's F5 gene novel variant. Thromboelastography (TEG) and TGA were utilized to detect and evaluate the coagulation function of proband and heterozygous carrier family members.
resultsThe proband was a middle-aged Chinese woman with menorrhagia, presenting as an FV deficiency patient with FV activity and antigen levels of 7% (reference: 86%-114%) and 6% (reference: 70%-140%), respectively. Genetic testing revealed that proband carried compound heterozygous variants in F5 gene: c.6528+3A>T(IVS24+3A>T) and c.6665A>G(p.Asp2222Gly). Multiple online tools indicate that the novel variant represents a genuine splice-site, leading to the deletion of a fragment and triggering exon skipping. The TGA results indicate decreased thrombin generation capacity in the proband, while TEG showed prolonged clotting initiation time.
conclusionThe proband with hereditary factor V deficiency carries compound heterozygous variants, IVS24+3A>T and p.Asp2222Gly, which have led to alterations in clinical phenotype, genotype, and function. The IVS24+3A>T variant in the F5 gene is a novel splice-site variant reported here for the first time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.